The US FDA has granted Emergency Use Authorisation for GlaxoSmithKline plc (GSK) & Vir Biotech's drug Sotrovimab to treat mild-to-moderate Covid -19 in high risk adults & paediatric patients. The U.S. Food and Drug Administration cleared the drug, called VIR-7831 or sotrovimab, for people older than 12 with mild to moderate infection who are at risk of progressing to severe Covid-19, GSK said. The companies applied for authorization in March based on interim data showing the drug reduced hospitalization or death by 85% compared with a placebo. Sotrovimab will be available for appropriate patients diagnosed with COVID-19 in the U.S. in the coming weeks. GSK added on to saying that discussions with global regulators regarding authorisations in additional countries continue to advance.

Source: Mint May 27, 2021 03:56 UTC